A chromatography strip for diagnosing pregnancy, comprising: a conjugate pad; and a detection pad, wherein the conjugate pad comprises a first anti-human chorionic gonadotropin (hCG) monoclonal antibody and a signal detection labeling material, and wherein the detection pad is provided with test line 1 and test line 2 that are isolated, the test line 1 comprises a second-hCG monoclonal antibody, and the test line 2 comprises human chorionic gonadotropin (hCG), wherein: (a) the first anti-hCG monoclonal antibody recognizes a β-core fragment site of human chorionic gonadotropin (hCG), and wherein the second anti-hCG monoclonal antibody recognizes a different site of hCG which is not the β-core fragment site of hCG; (b) the first anti-hCG monoclonal antibody is linked to the signal detection labeling material before or during the development of a sample to form a first conjugate, wherein a complex in which hCG or hCG β core fragment (hCGβcf) is bound to the first conjugate is formed when hCG or hCGβcf is present in the sample, and wherein as the concentration of hCG or hCGβcf increases in the sample, the number of the formed complexes increases, and conversely, the number of bare conjugates which are not bound to hCG in the sample decreases; and (c) a complex in which normal hCG is bound to the first conjugate is captured on test line 1 to indicate a signal, and a complex in which hCGβcf is bound to the first conjugate is not captured on test line 1, and wherein a bare conjugate which is not bound to hCG or hCGβcf in the sample reacts with hCG immobilized at a certain amount on test line 2, thereby being captured on test line 2 to indicate a signal. a conjugate pad; and a detection pad, wherein the conjugate pad comprises a first anti-human chorionic gonadotropin (hCG) monoclonal antibody and a signal detection labeling material, and wherein the detection pad is provided with test line 1 and test line 2 that are isolated, the test line 1 comprises a second-hCG monoclonal antibody, and the test line 2 comprises human chorionic gonadotropin (hCG), wherein: (a) the first anti-hCG monoclonal antibody recognizes a β-core fragment site of human chorionic gonadotropin (hCG), and wherein the second anti-hCG monoclonal antibody recognizes a different site of hCG which is not the β-core fragment site of hCG; (b) the first anti-hCG monoclonal antibody is linked to the signal detection labeling material before or during the development of a sample to form a first conjugate, wherein a complex in which hCG or hCG β core fragment (hCGβcf) is bound to the first conjugate is formed when hCG or hCGβcf is present in the sample, and wherein as the concentration of hCG or hCGβcf increases in the sample, the number of the formed complexes increases, and conversely, the number of bare conjugates which are not bound to hCG in the sample decreases; and (c) a complex in which normal hCG is bound to the first conjugate is captured on test line 1 to indicate a signal, and a complex in which hCGβcf is bound to the first conjugate is not captured on test line 1, and wherein a bare conjugate which is not bound to hCG or hCGβcf in the sample reacts with hCG immobilized at a certain amount on test line 2, thereby being captured on test line 2 to indicate a signal. (a) the first anti-hCG monoclonal antibody recognizes a β-core fragment site of human chorionic gonadotropin (hCG), and wherein the second anti-hCG monoclonal antibody recognizes a different site of hCG which is not the β-core fragment site of hCG; (b) the first anti-hCG monoclonal antibody is linked to the signal detection labeling material before or during the development of a sample to form a first conjugate, wherein a complex in which hCG or hCG β core fragment (hCGβcf) is bound to the first conjugate is formed when hCG or hCGβcf is present in the sample, and wherein as the concentration of hCG or hCGβcf increases in the sample, the number of the formed complexes increases, and conversely, the number of bare conjugates which are not bound to hCG in the sample decreases; and wherein a complex in which hCG or hCG β core fragment (hCGβcf) is bound to the first conjugate is formed when hCG or hCGβcf is present in the sample, and wherein as the concentration of hCG or hCGβcf increases in the sample, the number of the formed complexes increases, and conversely, the number of bare conjugates which are not bound to hCG in the sample decreases; and (c) a complex in which normal hCG is bound to the first conjugate is captured on test line 1 to indicate a signal, and a complex in which hCGβcf is bound to the first conjugate is not captured on test line 1, and wherein a bare conjugate which is not bound to hCG or hCGβcf in the sample reacts with hCG immobilized at a certain amount on test line 2, thereby being captured on test line 2 to indicate a signal.